Two-year treatment persistence with subcutaneous abatacept in rheumatoid arthritis: results from the French cohort of the ASCORE study
Authors' conclusion
In current practice in France, the rate of subcutaneous abatacept persistence at 2 years was comparable with that of the intravenous form. Treatment persistence was higher when abatacept was used as first-line versus later-line biologic therapy.
Study context
- Population
- French rheumatoid arthritis (RA) patients who initiated subcutaneous abatacept between August 2014 and January 2017
- Participants
- 546 evaluable patients
- Exposure
- Subcutaneous abatacept persistence by number of previous biologic therapies (biologic-naive vs 1 vs ≥2 failures)
- Biologic-naiven = 281reference
- 1 biologic failuren = 134
- ≥2 biologic failuresn = 131
- Outcome
- Treatment maintenance, analysed according to the number of previous biologic therapies
- Follow-up
- 2 years
Methodological detailsreal-world, French cohort of the international ASCORE study
- Real-world
- French cohort of the international ASCORE study
Main finding
As reported in the abstract
Subcutaneous abatacept persistence
- Overall persistence
- 43.0% (95% CI 38.6-47.2)
Observational data: associations, not effects.
Further findings
Main reason for discontinuing abatacept
- Lack of efficacy
- 46.6%
Original publication
Two-year treatment persistence with subcutaneous abatacept in rheumatoid arthritis: results from the French cohort of the ASCORE study. Clin Exp Rheumatol. Published 7 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →